Navigation Links
Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML)
Date:12/10/2007

Unique monoclonal antibody successfully targets human leukemic stem cells

ATLANTA, Dec. 10 /PRNewswire/ -- CSL Limited, Australia's leading biopharmaceutical company, has today presented data at the American Society of Hematology (ASH) 49th annual meeting, which demonstrate the promising pre-clinical activity of a novel monoclonal antibody, in the potential treatment of acute myeloid leukemia (AML).

AML is an aggressive cancer of white blood cells and most commonly occurs in adults. It is usually treated with chemotherapy but the cure rate in adults is only about 30%. About 9,000 deaths from AML occur each year in the United States(1). The novel antibody specifically targets the "core cell" of AML, called the leukemic stem cell (LSC) which was first identified in the laboratory of Professor John Dick, one of the key authors of the study(2). It is currently thought that the resistance of leukemic stem cells to chemotherapy is a major reason for the inability to cure most AML, and that improving the outlook for patients with AML will require elimination of these cells.

The antibody used in the research, called 7G3, was first created by Dr Angel Lopez at the Hanson Centre for Cancer Research in Adelaide, South Australia. It hones in on CD123 (IL-3 receptor alpha chain) on the surface of the LSC, blocking its function, growth and survival. CD123 is found on the surface of normal blood stem cells much less frequently, and 7G3 should therefore have no effect on normal blood cell development.

The research presented at the ASH meeting by key investigator Associate Professor Richard Lock of Children's Cancer Institute Australia for Medical Research in Sydney, describes the results of treatment with 7G3 of irradiated immune-deficient mice with AML.

Two central experiments were undertaken; firstly human AML stem cells were treated with 7G3 and then injected into the mice, which were compared with a control group of mice injected with untr
'/>"/>

SOURCE CSL Limited
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
3. Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
6. Isis Reports Preclinical Data Supporting Liver Safety of ISIS 301012
7. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
8. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
9. Tezampanel, TorreyPines Therapeutics Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
10. Telik Announces Presentation of Preclinical Data on Dual Inhibitors of Aurora Kinases and VEGFR2
11. CorNova Preclinical Results of Valecor Platinum(TM) Coronary Stent Studies Presented at TCT 2007 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... and MENLO PARK, Calif. , ... (OTCQX: DMPI) ("DelMar" and the "Company"), a ... cancer therapies in new orphan drug indications, today ... and accredited investors for a registered direct placement ... and 3.35 million common stock purchase warrants for ...
(Date:7/27/2015)... --  DocResponse was ranked the most accurate ... peer-reviewed study , "Evaluation of symptom checkers for ... the July issue of The British Medical Journal ... researchers determined that performance of online symptom checkers ... first in standardized patient evaluations more often than ...
(Date:7/27/2015)... Research and Markets ( http://www.researchandmarkets.com/research/7lz2fk/intraoperative ) has ... by Type (Intraoperative CT, Intraoperative MRI, Intraoperative Ultrasound) , ... Forecast to 2019" report to their offering. ... value of $2.1 Billion by 2019 from $1.8 Billion ... forecast period. The intraoperative imaging market ...
Breaking Medicine Technology:DelMar Pharmaceuticals Announces Financing Update and Initial Subscriptions of $2.0 million in Registered Direct Offering 2DelMar Pharmaceuticals Announces Financing Update and Initial Subscriptions of $2.0 million in Registered Direct Offering 3Harvard Study Finds DocResponse Most Accurate Medical Symptom Checker/Diagnostics Application 2Harvard Study Finds DocResponse Most Accurate Medical Symptom Checker/Diagnostics Application 3Global Intraoperative Imaging (Intraoperative CT, Intraoperative MRI, Intraoperative Ultrasound) Market Forecasts & Trends 2015-2019 2
... 17, 2012  Boston Scientific Corporation (NYSE: BSX ... market launch of the Epic™ Vascular Self-Expanding Stent System.  ... in patients with iliac artery stenosis, a form of ... by insufficient blood flow.  "The Epic ...
... RARITAN, N.J., May 17, 2012 Janssen Pharmaceuticals, ... Phase 3 study suggesting NUCYNTA® ER (tapentadol) extended-release ... providing pain management among adults with chronic moderate ... of the study were presented at the 31st ...
Cached Medicine Technology:Boston Scientific Announces FDA Approval and U.S. Launch of EPIC™ Vascular Stent 2Boston Scientific Announces FDA Approval and U.S. Launch of EPIC™ Vascular Stent 3Boston Scientific Announces FDA Approval and U.S. Launch of EPIC™ Vascular Stent 4Boston Scientific Announces FDA Approval and U.S. Launch of EPIC™ Vascular Stent 5Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 2Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 3Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 4Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 5Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 6Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 7Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 8Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 9Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 10Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 11Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 12
(Date:7/27/2015)... ... 27, 2015 , ... The heroin epidemic is affecting the Charlotte in North ... 7th. The rate for heroin usage has continued to climb around the country in ... less expensive alternative for those with an addiction to prescription opiate medications. According to ...
(Date:7/27/2015)... ... , ... On July 14, 2015, Harper’s Bazaar Magazine in an article titled ... such as stretch marks , fine lines , and acne scars ... listed include lasers, ultrasound, radio frequency, Botox, and dermal fillers. It is pointed out ...
(Date:7/27/2015)... ... July 27, 2015 , ... The Maricopa Community Colleges ... of the foster care system to get into and complete college. , The ... introduced at an event today with partners from across the valley. , The initiative ...
(Date:7/27/2015)... ... July 27, 2015 , ... ... Calcium Propionate industry is a professional and in-depth research report. The report ... chain structure, international market analysis etc. This report covers the global (US, ...
(Date:7/27/2015)... , ... July 27, 2015 , ... Throughout its 20 ... premier doctors and medical providers working on a lien basis. As the personal ... wide range of providers from chiropractors, to orthopedists, to pain management physicians, to psychologists ...
Breaking Medicine News(10 mins):Health News:45% Of People Addicted to Heroin Began Addicted to Prescription Medications 2Health News:45% Of People Addicted to Heroin Began Addicted to Prescription Medications 3Health News:The Latest Treatment Options for Seven Common Skin Issues 2Health News:Maricopa Community Colleges Launch Program To Help Youth In Foster Care Finish College 2Health News:Maricopa Community Colleges Launch Program To Help Youth In Foster Care Finish College 3Health News:Calcium Propionate Market Global Suppliers and Manufacture Analysis 2Health News:Calcium Propionate Market Global Suppliers and Manufacture Analysis 3Health News:Doctors on Liens Adds Highly Respected Physical Therapy Office in Los Angeles 2
... Sept. 9 As the nation awaits President Obama,s address ... The Philanthropic Collaborative (TPC) sent today a letter to the ... community foundations in the field of health. , , ... in the social and economic effectiveness of health-related philanthropic activities. ...
... that the sexual transmitted infection known as Trichomonas ... prostate cancer in a study published online September 9 ... . Jennifer Rider Stark, ScD, of the department ... in Boston, and colleagues conducted a case-control study nested ...
... , , , WASHINGTON, Sept. ... guest of President Barack Obama tonight for the President,s historic speech ... nation. , , As Co-Chair of the ... spearheading a bold campaign encouraging mayors around the country to urge ...
... Imaging technology might advance treatment of psychotic disorders, researchers ... technology has helped researchers pinpoint the part of the ... as schizophrenia begin, a new study says. , The ... in their early stages and help scientists develop more ...
... Republican Congressman Slated to Oppose President Obama,s Health Care Plan ... , , WASHINGTON, Sept. 9 Public ... Charles Boustany (R-La.) and the expected opposing remarks he will deliver ... session of Congress on health care reform. , , ...
... , , , KEYSTONE TREATMENT AND ... SIMILAR EVENTS TO FOLLOW AT CANTON AT 1 PM: , ... Media welcome at both locations , , SIOUX ... Sioux Falls, S.D. will be the 2009 national headquarters at 11 AM Wednesday, ...
Cached Medicine News:Health News:In Letter to President, TPC Highlights Foundation Grants in Health 2Health News:In Letter to President, TPC Highlights Foundation Grants in Health 3Health News:JNCI news brief: STD confirmed to be associated with increased risk of prostate cancer 2Health News:Mayor Gavin Newsom to Be President Obama's Guest for Healthcare Reform Speech to the Nation 2Health News:Brain Scans Could Help Spot Schizophrenia Earlier 2Health News:Rep. Boustany Hauled in $1.25 Million From Health and Insurance Industry 2Health News:Wed., Sept. 16, 11 AM News Conference: Sioux Falls' Keystone Treatment Center Is National HQ to Lead 100 Locations Nationwide in Balloon Liftoff Celebrating Recovery Against New Wave of Drug Abuse; Former U.S. Drug Czar/4-Star Gen. Barry McCaffrey, Lieute 2
... The REFLEXION 1st MPJ IMPLANT SYSTEM ... the primary reconstruction of the 1st metatarsal ... traumatic arthritis or revision of a previous ... achieve three goals: pain relief, superior function ...
... The hands play an important part in ... impairments and rheumatic changes can cause severe ... of the finger-joint prostheses was to produce ... the natural function as nearly possible.,The cementless ...
... The OSTEOMED 3.0/4.0mm CANNULATED SCREW SYSTEM ... Orthopedic Hand surgeon and Podiatrist, can be ... fusions. The system features two simplified ... Both screw sizes utilize one unique set ...
... the lower extremity for prepping before hip or ... procedures and particularly helpful for supporting the leg ... By holding the foot/ankle in an externally rotated ... which helps eliminate the need for manual support.,The ...
Medicine Products: